Dmitry Balyasny’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-50,000
Closed -$1.44M 2698
2024
Q3
$1.44M Buy
+50,000
New +$1.85M ﹤0.01% 1819
2023
Q3
Sell
-347,000
Closed -$31.6M 2232
2023
Q2
$31.6M Buy
+347,000
New +$29.9M 0.07% 382

Other funds holding APLS

Dmitry Balyasny's APLS Position: Q2 2026 in Review

Dmitry Balyasny sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,917,501 shares — an estimated $77.1M sold.

Dmitry Balyasny first reported a position in APLS in Q2 2018 and held it in 14 quarters. The position peaked at $77.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Dmitry Balyasny reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,917,501 Apellis Pharmaceuticals shares in Q2 2026, an estimated $77.1M.
  • Dmitry Balyasny first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 14 quarters.
  • Dmitry Balyasny's Apellis Pharmaceuticals position peaked at $77.1M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.